ArticleChemistry & biodiversity2026
Evaluating the Anticancer and Anti-Angiogenic Efficacy of Bergaptol in 2D and 3D Tumor Microtissue Models.
Article in Chemistry & biodiversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Furanocoumarins are plant-derived compounds with diverse biological activities and emerging therapeutic potential. This study evaluated the anticancer and anti-angiogenic properties of bergaptol by using MDA-MB-231, HepG2, and HeLa cancer cell lines, as well as HUVEC endothelial cells, with HDFs serving as the healthy control group. Cell viability, apoptosis, cell-cycle progression, and angiogenesis were evaluated using complementary two-dimensional (2D) and three-dimensional (3D) experimental models. Bergaptol exhibited selective cytotoxicity toward cancer and endothelial cells, with no apparent cytotoxicity toward HDFs. Treatment induced apoptosis, disrupted cell-cycle progression, and suppressed angiogenic activity. In 3D models, bergaptol reduced spheroid viability, diminished spheroid size, and decreased endothelial cell content. An ex vivo assay, the chorioallantoic membrane (CAM) assay, corroborated these observations, demonstrated a substantial inhibition of neovascularization, and further supports its anti-angiogenic potential. These findings demonstrate that bergaptol exhibits both anticancer and anti-angiogenic activity in 2D and 3D experimental models supporting further evaluation of bergaptol as a potential anticancer agent.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.